Statement: SkinBioTherapeutics Announcement

AI SummaryClose X

OptiBiotix Health plc has issued a statement addressing market uncertainty stemming from recent announcements by SkinBioTherapeutics (SBTX), in which OptiBiotix holds a 5.64% stake, confirming no current intention to sell these shares or its ProBiotix Health (PBX) shares. The company reported an unaudited cash position exceeding £1 million as of December 31, 2025, with no immediate need for fundraising, and is focused on increasing sales, improving margins, and reducing costs. Significant progress has been made in growing sales, with 2026 orders exceeding £800K, and each business unit is tasked with covering direct costs by the end of 2026, with its Amazon account now profitable and China Ecommerce anticipated to follow.

Disclaimer*

UK 100

Latest directors dealings